Neuroendocrine carcinoma of the skin+9
Not recruitingStudy on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy
Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy
- Disease:Neuroendocrine carcinoma of the skinColorectal cancer+8
- Substances:AtezolizumabAvelumab+5
France- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Unicancer







